Interleukin-8 associated with chemosensitivity and poor chemotherapeutic response to gastric cancer | Zendy

Sirikan Limpakan | Zendy; Pattama Wongsirisin | Zendy; Supachai Yodkeeree | Zendy; Bandhuphat Chakrabandhu | Zendy; Wilaiwan Chongruksut | Zendy; Pornngarm Limtrakul | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interleukin-8 associated with chemosensitivity and poor chemotherapeutic response to gastric cancer

Author(s) -

Sirikan Limpakan,

Pattama Wongsirisin,

Supachai Yodkeeree,

Bandhuphat Chakrabandhu,

Wilaiwan Chongruksut,

Pornngarm Limtrakul

Publication year - 2019

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.084

H-Index - 39

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo.2019.09.02

Subject(s) - oxaliplatin , medicine , irinotecan , cisplatin , chemotherapy , chemosensitivity assay , ex vivo , cancer , oncology , gastroenterology , in vivo , pharmacology , colorectal cancer , biology , microbiology and biotechnology

Gastric cancer (GC) patients have been found to have developed chemotherapy resistance that has resulted in a lowering of their overall survival rates. Interleukin-6 (IL-6) and interleukin-8 (IL-8) could be responsible as the predictive biomarkers in monitoring drug resistance. We have developed a protocol to monitor drug treatment by testing ex vivo chemosensitivity and cytokine levels of primary gastric cultures obtained from endoscopic biopsies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research